← Issue №13/ week of Sep 27, 2026/Colorectal

Vaccines for Cancer: A Translational Science Review.

From GI Signals issue №13: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal review · Sep 21, 2026 · JAMA · IF 63.1

Vaccines for Cancer: A Translational Science Review.

New evidencetranslationalbasic sciencebiomarker
Clinical takeawayConsider Sipuleucel-T for metastatic castrate-resistant prostate cancer and talimogene laherparepvec for advanced melanoma, as these are approved therapies with demonstrated benefits. Many other cancer vaccines remain investigational.
What it foundSipuleucel-T reduced all-cause mortality in metastatic castrate-resistant prostate cancer (32% vs 23%; HR 0.78 [95% CI, 0.61-0.98]) and talimogene laherparepvec increased 6-month response rates in advanced melanoma (16.3% vs 2.1%; OR 8.9).
ContextReviews emerging vaccine strategies (neoantigens, whole tumor cells, intratumoral injection) alongside approved vaccines (Sipuleucel-T, talimogene laherparepvec) with survival and response benefits in select cancers.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Disis ML … Cecil DL · JAMA · IF 63.1 · PubMed ↗Permalink
← Read the whole of issue №13 Every paper GI Signals surfaces gets a page like this one. All issues